• Executive Summary o Market Overview • Market Landscape o Market ecosystem o Value chain analysis • Market Sizing o Market definition o Market segment analysis o Market size 2019 o Market outlook: Forecast for 2019 - 2024 • Five Forces Analysis o Five Force Summary o Bargaining power of buyers o Bargaining power of suppliers o Threat of new entrants o Threat of substitutes o Threat of rivalry o Market condition • Market Segmentation by Dosage o Market segments o Comparison by Dosage o 0.30gm - Market size and forecast 2019-2024 o 0.15gm - Market size and forecast 2019-2024 o 0.50gm - Market size and forecast 2019-2024 o Market opportunity by Dosage • Market Segmentation by Age Group o Market segmentation by Age Group • Market Segmentation by End-user o Hospitals and clinics o Individuals • Customer landscape • Geographic Landscape o Geographic segmentation o Geographic comparison o North America - Market size and forecast 2019-2024 o Europe - Market size and forecast 2019-2024 o Asia - Market size and forecast 2019-2024 o ROW - Market size and forecast 2019-2024 o Key leading countries o Market opportunity by geography o Volume driver – demand-led growth o Market challenges o Market trends • Vendor Landscape o Vendor landscape o Landscape disruption o Competitive Scenario • Vendor Analysis o Vendors covered o Market positioning of vendors o Adamis Pharmaceuticals Corp. o ALK-Abello AS o Amneal Pharmaceuticals Inc. o Bausch Health Companies Inc. o kaleo Inc. o Lincoln Medical Ltd. o Mylan NV o Novartis AG o Pfizer Inc. o Teva Pharmaceutical Industries Ltd. • Appendix o Scope of the report o Currency conversion rates for US$ o Research methodology o List of abbreviations Exhibit • 1: Key Finding 1 • 2: Key Finding 2 • 3: Key Finding 3 • 4: Key Finding 5 • 5: Key Finding 6 • 6: Key Finding 7 • 7: Key Finding 8 • 8: Parent market • 9: Market characteristics • 10: Offerings of vendors included in the market definition • 11: Market segments • 12: Global - Market size and forecast 2019 - 2024 ($ million) • 13: Global market: Year-over-year growth 2019 - 2024 (%) • 14: Five forces analysis 2019 & 2024 • 15: Bargaining power of buyers • 16: Bargaining power of suppliers • 17: Threat of new entrants • 18: Threat of substitutes • 19: Threat of rivalry • 20: Market condition - Five forces 2019 • 21: Other1 - Market share 2019-2024 (%) • 22: Comparison by Other1 • 23: 0.30gm - Market size and forecast 2019-2024 ($ million) • 24: 0.30gm - Year-over-year growth 2019-2024 (%) • 25: 0.15gm - Market size and forecast 2019-2024 ($ million) • 26: 0.15gm - Year-over-year growth 2019-2024 (%) • 27: 0.50gm - Market size and forecast 2019-2024 ($ million) • 28: 0.50gm - Year-over-year growth 2019-2024 (%) • 29: Market opportunity by Other1 • 30: Customer landscape • 31: Market share by geography 2019-2024 (%) • 32: Geographic comparison • 33: North America - Market size and forecast 2019-2024 ($ million) • 34: North America - Year-over-year growth 2019-2024 (%) • 35: Europe - Market size and forecast 2019-2024 ($ million) • 36: Europe - Year-over-year growth 2019-2024 (%) • 37: Asia - Market size and forecast 2019-2024 ($ million) • 38: Asia - Year-over-year growth 2019-2024 (%) • 39: ROW - Market size and forecast 2019-2024 ($ million) • 40: ROW - Year-over-year growth 2019-2024 (%) • 41: Key leading countries • 42: Market opportunity by geography ($ million) • 43: Impact of drivers and challenges • 44: Vendor landscape • 45: Landscape disruption • 46: Industry risks • 47: Vendors covered • 48: Market positioning of vendors • 49: Adamis Pharmaceuticals Corp. - Overview • 50: Adamis Pharmaceuticals Corp. - Product and service • 51: Adamis Pharmaceuticals Corp. - Key offerings • 52: Adamis Pharmaceuticals Corp. - Key customers • 53: Adamis Pharmaceuticals Corp. - Segment focus • 54: ALK-Abello AS - Overview • 55: ALK-Abello AS - Product and service • 56: ALK-Abello AS - Key offerings • 57: ALK-Abello AS - Key customers • 58: ALK-Abello AS - Segment focus • 59: Amneal Pharmaceuticals Inc. - Overview • 60: Amneal Pharmaceuticals Inc. - Business segments • 61: Amneal Pharmaceuticals Inc. - Key offerings • 62: Amneal Pharmaceuticals Inc. - Key customers • 63: Amneal Pharmaceuticals Inc. - Segment focus • 64: Bausch Health Companies Inc. - Overview • 65: Bausch Health Companies Inc. - Business segments • 66: Bausch Health Companies Inc. - Key offerings • 67: Bausch Health Companies Inc. - Key customers • 68: Bausch Health Companies Inc. - Segment focus • 69: kaleo Inc. - Overview • 70: kaleo Inc. - Product and service • 71: kaleo Inc. - Key offerings • 72: kaleo Inc. - Key customers • 73: kaleo Inc. - Segment focus • 74: Lincoln Medical Ltd. - Overview • 75: Lincoln Medical Ltd. - Product and service • 76: Lincoln Medical Ltd. - Key offerings • 77: Lincoln Medical Ltd. - Key customers • 78: Lincoln Medical Ltd. - Segment focus • 79: Mylan NV - Overview • 80: Mylan NV - Business segments • 81: Mylan NV - Key offerings • 82: Mylan NV - Key customers • 83: Mylan NV - Segment focus • 84: Novartis AG - Overview • 85: Novartis AG - Business segments • 86: Novartis AG - Key offerings • 87: Novartis AG - Key customers • 88: Novartis AG - Segment focus • 89: Pfizer Inc. - Overview • 90: Pfizer Inc. - Business segments • 91: Pfizer Inc. - Key offerings • 92: Pfizer Inc. - Key customers • 93: Pfizer Inc. - Segment focus • 94: Teva Pharmaceutical Industries Ltd. - Overview • 95: Teva Pharmaceutical Industries Ltd. - Business segments • 96: Teva Pharmaceutical Industries Ltd. - Key offerings • 97: Teva Pharmaceutical Industries Ltd. - Key customers • 98: Teva Pharmaceutical Industries Ltd. - Segment focus • 99: Currency conversion rates for US$ • 100: Research Methodology • 101: Validation techniques employed for market sizing • 102: Information sources • 103: List of abbreviations

Adamis Pharmaceuticals Corp., ALK-Abello AS, Amneal Pharmaceuticals Inc., Bausch Health Companies Inc., kaleo Inc., Lincoln Medical Ltd., Mylan NV, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd.